scholarly journals Clinical importance of Clostridium difficile finding in hospitalized patients

2008 ◽  
Vol 61 (11-12) ◽  
pp. 632-637 ◽  
Author(s):  
Branislava Kocic ◽  
Predrag Stojanovic
Keyword(s):  
Clostridium Difficile ◽  
Antibiotic Treatment ◽  
Clinical Importance ◽  
Hospitalized Patients ◽  
Control Group ◽  
Clinical Group ◽  
Clinical Center ◽  
Significant Difference ◽  
Clostridium Difficile Toxin ◽  
Stool Samples

Introduction Clostridium difficile infections predominatelly occur among hospitalized patients. The aim of this study was to evaluate the importance of finding the isolate of Clostridium difficile cultured from the stool of hospitalized patients. Material and methods Material consisted of 100 patients with at least one liquid stool samples and control group with form stool. Every patient spent minimum 48h in hospital before the sampling. The material was immediately cultured on mediums for isolation of enteric pathogens, and on selective CCFA medium (Biomedics) for Clostridium difficile in anaerobic condition. Diagnosis of Clostridium difficile toxin in stool samples was achieved by ELISA-RIDASCREEN Clostridium difficile Toxin A/B test (R-Biopharm). Results One-hundred forty one stool samples of patients in Clinical Center Nis were cultivated and examined for C. difficile. The bacteria was isolated in seven patients from the clinical group. In four (57.14%) patients, the presence of C. difficile toxin in stool was established. The bacteria was diagnosed from the stool samples of five patients from the control group, but the toxin was not found in their stool samples. Discussion The results performed at the Institute for Public Health Nis are in accordance with previously published results that all patients with positive findings of Clostridium difficile toxin in stool samples were on antibiotic treatment longer than 14 days. By analyzing the patient's stay in hospital and duration of antibiotic treatment, we observed the statistically significant difference in findings between the patients with CDAD and the patients from the control group with positive bacteria. Conclusion The study confirms the importance of finding Clostridium difficile associated disease in four (4%) hospitalized patients.

scholarly journals Detection of Clostridium difficile toxins A and B from Antibiotic- Associated Diarrhea and Colitis in Iraqi children, by ELISA Test

2015 ◽  
Vol 39 (2) ◽  
pp. 7-11
Author(s):  
Luma Yousif Mahdi
Keyword(s):  
Clostridium Difficile ◽  
Elisa Test ◽  
Control Group ◽  
Healthy Children ◽  
Elisa Method ◽  
Toxin A ◽  
Antibiotic Associated Diarrhea ◽  
Clostridium Difficile Toxin ◽  
Clostridium Difficile Toxin A ◽  
Stool Samples

     This study focuses on diagnosis of Clostridium difficile causing Antibiotic – Associated diarrhea and colitis by Elisa method and to detect of C. difficile Toxin A and B in stool samples by Elisa test. Two hundred forty (240) stool samples were collected from children suffering from antibiotic- associated diarrhea and Colitis cases at ages from after birth to 15 years old from Baghdad hospitals. Samples were taken during the period of first of June 2013 until the end of April 2014. In addition to that 80 samples from healthy children of the same age and sex as a control group. Clostridium difficile Toxin A and B in stool samples were detected. Results of this study indicated that females were more infected than males. Overall positivity was 21.25% in present studied group compared to controls (P<0.05). In conclusion, the majority percent from age <1year 15% and this percent decreased with the advance in age.

scholarly journals Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients

2012 ◽  
Vol 43 (1) ◽  
pp. 215-223 ◽  
Author(s):  
Predrag Stojanovic ◽  
Branislava Kocic ◽  
Miodrag Stojanovic ◽  
Biljana Miljkovic-Selimovic ◽  
Suzana Tasic ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clinical Importance ◽  
Hospitalized Patients ◽  
Stool Samples

scholarly journals Detection of Clostridium difficile Infection in Al-Quwayiyah General Hospital, Riyadh, Kingdom of Saudi Arabia

2020 ◽  
pp. 94-102
Author(s):  
Enas Sh. Khater ◽  
Abd Alazim A. Al- Faki
Keyword(s):  
Saudi Arabia ◽  
Abdominal Pain ◽  
Clostridium Difficile ◽  
Proton Pump ◽  
Peptic Ulcers ◽  
Pcr Assay ◽  
Kingdom Of Saudi Arabia ◽  
Statistical Significant Difference ◽  
Significant Difference ◽  
Stool Samples

Clostridium difficile infections (CDIs) is considered healthcare-associated infections which cause watery diarrhea to long stayed hospitalized patients and cause increased mortality rate. Aim: Detection of the prevalence and risk factors of C. difficile in Al Quwayiyah General hospital, Riyadh, Kingdom of Saudi Arabia and compairing between GeneXpert® PCR assay and Quikchek complete-enzyme imunoassay QCC, (QCC-EIA) in detection of C. difficile infection and toxicity Materials and Methods: A cross sectional and prospective study was performed for one year started from June 2019 to June 2020. The data collected include demographic, laboratory and clinical data. A total of 104 stool samples were collected from patients presented with diarrhea. GeneXpert® PCR assay and Quikchek complete-enzyme imunoassay QCC (QCC-EIA) were conducted to each stool sample. Results: Only 15(14.4%) of the 104 studied patients had CDI while 89 (85.6%) were non CDI patients, 13 (86.7%) of the CDI patients were males and 2 (13.3%) were females with mean age for CDI cases 61 (±19.9), while non CDI cases involved 55(61.8%) were males and 34 (38.2%) were females with mean age for cases of non CDI, 60 (±18.7) years. Of the CDI and non CDI cases respectively 12 (80%) and 14(15.7%) had fever, 5 (27%) and 6 (6.7%) had vomitting and 7 (46.7%) and 12 (13.5%) of cases had abdominal pain. There was statistical significant difference between patients with fever while no statistical significant difference regarding vomitting and abdominal pain. There was statistical significant difference between patients with peptic ulcers, patients received proton pump inhibitors and patients received broad-spectrum antibiotics, while There was no statistical significant difference between cardiac disease, cerebrovascular disease, diabetes, pulmonary disease, hepatic disease and Renal disease. Gene expert PCR detected 15/104(14.4%) as positive CDI while QCC-EIA detected 21/104 (20.5%) as positive CDI. On comparison between gene expert PCR technique and QCC-EIA the sensitivity of QCC-EIA was 100%, while the specificity was 91%. The Positive Predictive Value was 74%, while the Negative Predictive Value was 100%. Conclusion: The C. difficile infection prevalence rate in the hospital was 14.4%. There was statistical significant difference between patients with peptic ulcers, patients received proton pump inhibitors and patients received broad-spectrum antibiotics. The QCC-EIA can be used as a screening test for the detection of C. difficile toxin in stool samples but should be confirmed with a PCR assay or another confirmatory test Due to its decreased specificity.

Latex agglutination test for detection of Clostridium difficile toxin in stool samples.

1984 ◽  
Vol 20 (3) ◽  
pp. 339-341 ◽  
Author(s):  
M S Shahrabadi ◽  
L E Bryan ◽  
D Gaffney ◽  
S E Coderre ◽  
R Gordon ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Latex Agglutination ◽  
Agglutination Test ◽  
Latex Agglutination Test ◽  
Clostridium Difficile Toxin ◽  
Stool Samples

scholarly journals Efficacy of Levamisole with Standard Care Treatment vs Standard Care in Clinical Presentations of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial

2021 ◽  
Author(s):  
Mohammad Hossein Asgardoon ◽  
Hamid Emadi koochak ◽  
Mohammad Hassan Kazemi-Galougahi ◽  
Ali Zare Dehnavi ◽  
Behzad Khodaei ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
General Health ◽  
Standard Care ◽  
Intervention Group ◽  
Health Condition ◽  
Hospitalized Patients ◽  
Care Group ◽  
Control Group ◽  
Significant Difference ◽  
General Health Condition

Abstract Introduction: Levamisole (LVM) demonstrated clinical benefit in a trial in patients with mild to moderate coronavirus disease 2019 (COVID-19), but its effect in a larger sample size needs to be confirmed. Methods In this randomized open-label trial, we enrolled non-hospitalized patients with mild to moderate COVID-19 at nine health centers in Tehran province, Iran, in 2021. Patients were randomly assigned to receive a 10-day course of LVM with standard care (n = 185), or standard care (n = 180) in a 1:1 ratio. On days 1 to 10, LVM was administered orally at a dosage of 50 mg. The participants were called and followed on days 1, 3, 5, 7, 9, and 14. The outcomes were general health condition, hospitalization rate, sign and symptoms, and adverse events (AEs). Generalized Estimating Equations model was used for analysis. Results Among 507 randomized patients, 473 started the experiment and received LVM in addition to standard care or received only the standard care (median age, 40 [IQR, 32-50.75] years; 164 [44.9%] women; 9.4% had diabetes, 8.8% hypertension, 1.6% cardiovascular disease), and 346 (98%) completed the trial. Compared to control group, LVM decreased the general health condition of the patients (B=-0.635; CI= -0.041, -0.329; P= 0.000). Patients in the LVM with standard care group had significantly lower odds of developing fever (OR= 0.260; 95% CI= ‎0.11‎‎3‎-0.59‎‎9‎; P = .002), chills (OR= 0.223; 95% CI= ‎‎0.07‎‎6‎-‎0.64‎‎8‎; P = 0.006), fatigue (OR= 0.576; 95% CI= ‎0.34‎‎6‎-‎0.96‎‎0‎‎; P = ‎0.034), and myalgia (OR= 0.54‎‎4‎; 95% CI= ‎0.31‎‎7‎-‎0.93‎‎2‎‎; P =0.027). During the therapy, there was no significant difference in the parameters of dyspnea, cough, diarrhea, nausea, vomiting, sore throat, hyposmia, dysgeusia, and anorexia (P > 0.05). No significant difference was observed in the rate of hospitalization. Although the intervention group had greater AEs than the control group, yet, the difference was not statistically significant. Conclusions LVM has clinical benefit in improving health condition of patients with mild to moderate COVID-19. Further studies are needed to confirm our findings. Trial Registration: Iranian Registry of Clinical Trials: IRCT20201124049480N1; Registration date: 28/03/2021.

scholarly journals Resilience of Adolescents Diagnosed with Anxiety and Their Parents in Clinical Sample

2021 ◽  
Vol 4 (1) ◽  
pp. 58
Author(s):  
Krisztina Törő ◽  
Szabolcs Takács ◽  
Gábor Csikós
Keyword(s):  
Anxiety Disorders ◽  
Positive Relationship ◽  
Protective Factor ◽  
Clinical Sample ◽  
Control Group ◽  
Clinical Group ◽  
Psychiatric Problem ◽  
Resilience Scale ◽  
Significant Difference ◽  
Psychological Difficulties

Anxiety disorder is the most frequent psychiatric problem among children and adolescents. Research proved that resilience can be a protective factor in coping with psychological difficulties. Our research focuses on these aspects of resilience. Aims: We aimed to investigate the resilience and anxiety level of families with adolescents who were diagnosed with anxiety disorders. The clinical sample included 40 adolescents who were diagnosed with anxiety disorders and who received ambulant treatment. (18 boys and 22 girls; age: M=13.37 years, SD=1.46). Members of the control group were recruited from schools and they were normally developing adolescents without any psychiatric diagnosis. (18 boys and 19 girls, age: M=13.7 years; SD=1.56) DASS-21, Ten items Connor-Davidson Resilience Scale and self-made demographic sheet were used. Regarding the resilience, a Significant difference was found between the clinical and the sample group both among the mothers and their children. However, in the case of fathers, no discrepancy was found. Our results suggest that there is a significant, moderate positive relationship between the resilience of the mother and their children. Nevertheless, similar mechanisms in the fathers’ case cannot be registered. In the control group, the fathers’ perception of their child’s resilience proved to be the strongest predictive factor (beta=0,495). On the contrary in the clinical group, the maternal perception was more accurate. (beta=0,06). Resilience can serve as a protective factor against anxiety. Our results can be useful for practitioners and draw attention to the importance of intrafamily mechanisms in coping with anxiety and mood disorders.

scholarly journals The Microbiota Diversity Following Antibiotic Treatment of Clostridium Difficile Infection

2020 ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Stool Samples

Abstract Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause diarrheal disease. A dominant risk factor is antibiotic treatment that disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to C. difficile infection (CDI) onset and patient gut microbiota.Methods: Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene using the Illumina MiSeq platform and QIIME2.Results: In total, 84 patients with C. difficile infection were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) had received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n=44 cases). The intestinal microbiota of the patients was not uniform. Differences in intestinal microbiome were influenced by the different combinations of antibiotics that the patients had received (p = 0.022)Conclusions: The number of different antibiotics administered has a major impact on the CDI patients gut microbiome, mainly on bacterial richness.

scholarly journals Microbiota diversity following antibiotic treatment of Clostridium difficile infection

2020 ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Stool Samples

Abstract Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause C. difficile infection (CDI), a diarrheal disease. A dominant risk factor is antibiotic treatment, which disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to CDI onset and patient gut microbiota during the infection.Methods: Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene, using the Illumina MiSeq platform and QIIME2.Results: In total, 84 patients with CDI were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n=44 cases). The intestinal microbiota of the patients was not uniform. Differences in intestinal microbiome were influenced by the different numbers of antibiotics families that the patients received (p = 0.022)Conclusions: The number of different antibiotics amount has a major impact on the gut microbiome of CDI patients, particularly on its bacterial richness.

Effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled study

2011 ◽  
Vol 125 (6) ◽  
pp. 620-625 ◽  
Author(s):  
C Cingi ◽  
M Songu ◽  
A Ural ◽  
N Erdogmus ◽  
M Yildirim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Group ◽  
Antibiotic Treatment ◽  
Clinical Signs ◽  
Chlorhexidine Gluconate ◽  
Controlled Study ◽  
Control Group ◽  
Control Groups ◽  
Significant Difference

AbstractObjective:To assess the effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray, used in conjunction with antibiotic treatment, on the intensity of clinical signs and quality of life of patients with group A streptococcal tonsillopharyngitis.Methods:Patients (n = 147) with streptococcal tonsillopharyngitis were recruited and randomly allocated to either the treatment group (penicillin plus chlorhexidine and benzydamine; n = 72) or control group (penicillin plus placebo; n = 75). Blinded assessments were conducted before and after 10 days' treatment, using an intensity rating scale for clinical sign severity, a visual analogue scale for subjective health state, the Short Form 36 Health Questionnaire for quality of life, and a customised questionnaire for side effects.Results:The treatment group showed a statistically significant reduction in the intensity of clinical signs, compared with the control group. On treatment day 7, there was no significant difference in quality of life between the treatment and control groups. The treatment drugs were well tolerated, and no serious adverse events were observed.Conclusion:Chlorhexidine gluconate and benzydamine hydrochloride mouth spray, added to standard antibiotic treatment, significantly alleviate the intensity of clinical signs in patients with streptococcal pharyngitis. Further research is needed using larger sample sizes or alternative control groups.

Sign in / Sign up

Export Citation Format

Share Document